Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Atallah E. reports personal fees from Novartis Services Inc. during the conduct of the study and personal fees from Bristol Myers Squibb, Takeda, and AbbVie, outside the submitted work. Maegawa R. is an employee and stockholder of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Corbin R. was an employee of Novartis Services Inc., East Hanover, NJ, USA, at the time of conduct of this study. Viana R. is an employee and stockholder of Novartis Pharma AG, Basel, Switzerland. Saini L. is an employee of Novartis Healthcare Pvt. Ltd., Hyderabad, India. Rajput T. was an employee of Novartis Healthcare Pvt. Ltd., Hyderabad, India at the time of conduct of this study."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Novartis Services Inc., East Hanover, NJ, USA."